Asset Details
Do you wish to reserve the book?
Management of fracture risk in CKD—traditional and novel approaches
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Management of fracture risk in CKD—traditional and novel approaches
Do you wish to request the book?
Management of fracture risk in CKD—traditional and novel approaches
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Management of fracture risk in CKD—traditional and novel approaches
2023
Overview
ABSTRACT
The coexistence of osteoporosis and chronic kidney disease (CKD) is an evolving healthcare challenge in the face of increasingly aging populations. Globally, accelerating fracture incidence causes disability, impaired quality of life and increased mortality. Consequently, several novel diagnostic and therapeutic tools have been introduced for treatment and prevention of fragility fractures. Despite an especially high fracture risk in CKD, these patients are commonly excluded from interventional trials and clinical guidelines. While management of fracture risk in CKD has been discussed in recent opinion-based reviews and consensus papers in the nephrology literature, many patients with CKD stages 3–5D and osteoporosis are still underdiagnosed and untreated. The current review addresses this potential treatment nihilism by discussing established and novel approaches to diagnosis and prevention of fracture risk in patients with CKD stages 3–5D. Skeletal disorders are common in CKD. A wide variety of underlying pathophysiological processes have been identified, including premature aging, chronic wasting, and disturbances in vitamin D and mineral metabolism, which may impact bone fragility beyond established osteoporosis. We discuss current and emerging concepts of CKD–mineral and bone disorders (CKD-MBD) and integrate management of osteoporosis in CKD with current recommendations for management of CKD-MBD. While many diagnostic and therapeutic approaches to osteoporosis can be applied to patients with CKD, some limitations and caveats need to be considered. Consequently, clinical trials are needed that specifically study fracture prevention strategies in patients with CKD stages 3–5D.
Lay Summary
Patients with chronic kidney disease (CKD) are at increased risk of fractures, causing disability, impaired quality of life and increased risk of death. Osteoporosis is a common cause of fractures, and different medications have the potential to reduce fracture risk in osteoporosis. Several diagnostic criteria have been developed to identify patients at risk of fracture who would benefit from treatment. However, in CKD, the identification of patients with increased fracture risk is complicated by mineral metabolism disturbances due to reduced kidney function. Furthermore, patients with more advanced CKD are often excluded from clinical trials and treatment recommendations for fracture risk reduction. This review discusses diagnostic possibilities and treatment options to reduce fracture risk in patients with CKD, based on disease mechanisms, clinical experience, and clinical and experimental research. Although more research is needed, we conclude that many diagnostic and therapeutic approaches to osteoporosis can be applied in patients with CKD.
Publisher
Oxford University Press (OUP),Oxford University Press
